HK1202256A1 - Psma as a biomarker for androgen activity in prostate cancer - Google Patents

Psma as a biomarker for androgen activity in prostate cancer Download PDF

Info

Publication number
HK1202256A1
HK1202256A1 HK15102796.5A HK15102796A HK1202256A1 HK 1202256 A1 HK1202256 A1 HK 1202256A1 HK 15102796 A HK15102796 A HK 15102796A HK 1202256 A1 HK1202256 A1 HK 1202256A1
Authority
HK
Hong Kong
Prior art keywords
psma
androgen
biomarker
prostate
prostate cancer
Prior art date
Application number
HK15102796.5A
Other languages
English (en)
Chinese (zh)
Inventor
Neil H. Bander
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of HK1202256A1 publication Critical patent/HK1202256A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15102796.5A 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer HK1202256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604039P 2012-02-28 2012-02-28
US61/604,039 2012-02-28
PCT/US2013/000051 WO2013130177A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Publications (1)

Publication Number Publication Date
HK1202256A1 true HK1202256A1 (en) 2015-09-25

Family

ID=49083148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102796.5A HK1202256A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Country Status (6)

Country Link
US (1) US20130315830A1 (cg-RX-API-DMAC7.html)
EP (1) EP2819704A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015508903A (cg-RX-API-DMAC7.html)
CA (1) CA2865774A1 (cg-RX-API-DMAC7.html)
HK (1) HK1202256A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013130177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
JP2020505034A (ja) 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
AU2018250336B2 (en) 2017-04-07 2025-02-20 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
CA3113080A1 (en) * 2018-09-28 2020-04-02 Imaginab, Inc. Cd8 imaging constructs and methods of use thereof
WO2022114675A1 (ko) * 2020-11-24 2022-06-02 한국과학기술연구원 전립선암 진단을 위한 바이오마커, 이들의 조합, 및 이의 용도
EP4267969A4 (en) * 2020-12-22 2025-02-12 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE337011T1 (de) * 2001-02-07 2006-09-15 Beth Israel Hospital Modifizierte psma-liganden und deren verwendung
AU2007227195A1 (en) * 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and Ly6 E: targets for cancer diagnosis and therapy
EP2209498A2 (en) * 2007-10-03 2010-07-28 Cornell University Treatment of proliferative disorders using antibodies to psma
US20100047166A1 (en) * 2008-08-20 2010-02-25 Kanner Steven B Antibodies and related molecules that bind to 58p1d12 proteins
EP2398504B1 (en) * 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP4420730A3 (en) * 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2010119001A1 (en) * 2009-04-14 2010-10-21 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
EP2817629A4 (en) * 2012-02-24 2016-01-13 Univ Cornell INCREASED PSMA VALUE AS IDENTIFIER OF DEADLY PROSTATE CANCER

Also Published As

Publication number Publication date
US20130315830A1 (en) 2013-11-28
EP2819704A4 (en) 2015-10-21
JP2015508903A (ja) 2015-03-23
CA2865774A1 (en) 2013-09-06
EP2819704A1 (en) 2015-01-07
WO2013130177A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
HK1202256A1 (en) Psma as a biomarker for androgen activity in prostate cancer
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012174256A3 (en) Dna methylation profiles in cancer
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EP3736294A3 (en) Cd73 blockade
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
WO2014026768A8 (en) Colorectal cancer markers
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
EP4356960A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
HK1213946A1 (zh) 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
WO2013043878A3 (en) Alternative splicing variants of genes associated with prostate cancer risk and survival
WO2011146568A8 (en) Predicting response to a her inhibitor
WO2011017534A3 (en) Treatment of prostate cancer
WO2014060848A3 (en) Treatment methods using adenovirus
WO2012143481A3 (en) Prostate cancer markers
WO2011146143A3 (en) Enzymatic activity of psa as diagnostic marker for prostate cancer
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
MX2013002155A (es) Compuestos para el tratamiento de cancer.